Shingles

About Shingles Clinical Trials (Click to Open)

Join Clinical Trials for Shingles

Shingles

General Purpose:

Shingles is the common term used to refer to a painful rash caused by the varicella-zoster virus, which is the same virus that causes chickenpox. This virus is part of the herpes group of viruses (which cause genital herpes and cold sores), therefore it is sometimes referred to as herpes zoster.

Following a case of the chickenpox, the virus lies dormant in the body; however, it can eventually become reactive and cause shingles to develop. Shingles has a very characteristic appearance, typically occurring as a single stripe of blisters that wraps around the torso, though the rash can also occur around an eye or on one side of the neck or face.

It can cause severe pain, burning, and numbness, as well as itching. The blisters can also break open and create a crust on the surface of the affected areas of the skin. In addition, it can be accompanied by fever, achiness, headache, and fatigue.

If left untreated, shingles that occurs near the eye can lead to permanent eye damage. Individuals over age 65 are at an increased risk of complications for shingles, as are those who have a weakened immune system. Complications include residual nerve pain, vision loss, facial paralysis, hearing or balance problems, and skin infections. 

Unfortunately there is no cure for shingles but quick treatment with anti-viral medicines can help to promote healing and reduce the risk of complications down the road. The good news is that researchers are hard at work searching for new and improved methods to treat shingles and its associated complications.

What Will Shingles Clinical Trials Be Like?

The types of procedures used in shingles clinical trials will ultimately depend on the specific nature of the study and what aspect related to shingles is being studied. Provided below is a list of common procedures, tests, and assessments that may be incorporated into such clinical trials:

  • Detailed physical examination
  • Questionnaires to evaluate your stress level, pain level, emotional well-being, and history of current and former illnesses.
  • Blood tests
  • Biopsy of shingles blisters
  • Photographs of your blisters
  • Use of lotions, creams, oral medications, or laser light therapy

Typical Shingles Clinical Trial Protocol:

Specific examples of clinical trials for shingles might include the following:

  • A randomized clinical trial in which patients with shingles are randomly assigned to receive treatment with standard antiviral therapy using acyclovir plus placebo, or a newly-developed antiviral medication.
  • A study to determine the safety and efficacy of an anti-shingles vaccine administered to elderly individuals.
  • A study to determine in individuals with shingles experience, improved pain control when relaxation techniques are incorporated into a comprehensive pain management plan that includes medication.
  • A randomized clinical trial to evaluate the safety and efficacy of a new pain medication in the treatment of shingles-related pain. In such a study, patients would randomly be assigned to receive standard therapy for shingles-related pain plus the new medication, or standard therapy for shingles-related pain plus a placebo.

A brief word about randomized trials and placebos:

Many clinical trials involve the comparison of an investigational treatment to a “standard” treatment. Some studies determine which therapy a patient receives through a process known as randomization, in which patients are randomly assigned to receive either the investigational treatment or the standard treatment.

On occasion, a trial will investigate the use of a standard treatment plus a new drug compared to standard treatment plus a placebo (such as the fourth clinical trial example provided above). Placebos are inactive or “sham” treatments that are identical in appearance to the active treatment but have no therapeutic value.

Placebos are necessary to help determine if adverse effects that occur during the clinical trial are the result of the investigational treatment or due to some other factor. They also allow researchers to measure the effects of the active treatment and observe what would have happened without it.

In rare instances where no standard therapy exists, or when a new drug or therapy is being investigated, the investigational treatment might be compared to a placebo alone (such as the first clinical trial example described above). In these types of trials, those patients who are randomized to the placebo group do not receive an active treatment.

It is important to know that placebo-only trials are only conducted when scientifically necessary and when patients have been adequately informed that they may end up receiving the placebo rather than the active treatment.

It is very important to note, however, that no one should ever participate in such a placebo trial when there is a widely available and highly effective standard treatment already in existence for their particular disease or condition.

Trial Eligibility and Medical Information Needed:

The type of clinical trial you may be eligible for often depends on many factors. Therefore, it is important to know as many details as possible with regard to your specific circumstances when searching for clinical trials.  Examples of information you may want to have on hand include the following:

  • Your history of chickenpox and shingles
  • Your prior and current diagnoses of any other health conditions or diseases
  • Your current medications (including vitamins, minerals, and other dietary supplements)

Suggested Search Terms:

 “shingles treatment,” “shingles prevention,” “shingles pregnancy,” “shingles recurrence,” “shingles complications,” “shingles children,” “shingles stress,” “shingles elderly,” “shingles pain,” and “shingles vaccine.”

 

Current Search Term:

“Shingles”

Add Comments or Questions



Zoster Eye Disease Study


Condition:   Herpes Zoster Ophthalmicus
Interventions:   Drug: Masked Placebo;   Drug: Masked Oral Valacyclovir
Sponsors:   New York University School of Medicine;   National Eye Institute (NEI);   National Institutes of Health (NIH)
Not yet recruiting - verified April 2017


Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients


Condition:   Herpes Zoster
Intervention:   Biological: Zostavax vaccine
Sponsor:   HaEmek Medical Center, Israel
Recruiting - verified February 2017


Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age


Condition:   Herpes Zoster
Intervention:   Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified April 2017


Herpes Zoster Prevalence in Frailty Consultations


Condition:   Herpes Zoster
Intervention:   Other: Medical Questionary
Sponsor:   University Hospital, Toulouse
Completed - verified July 2016



Optimal Timing of Zoster Vaccine After Zoster Illness


Condition:   Shingles
Intervention:   Biological: Zostavax
Sponsor:   Seoul National University Hospital
Recruiting - verified October 2016


Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster Vaccine GSK1437173A
Sponsor:   GlaxoSmithKline
Recruiting - verified May 2017


Immune Response to Shingles Vaccination


Condition:   Shingles
Intervention:   Drug: Zoster Vaccine Live
Sponsors:   University of Washington;   Merck Sharp & Dohme Corp.
Recruiting - verified October 2016


Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier


Condition:   Herpes Zoster
Intervention:   Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified January 2017


Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds


Conditions:   Shingles;   Herpes Zoster
Interventions:   Biological: Zostavax;   Biological: HZ/su vaccine;   Biological: Placebo
Sponsors:   University of Colorado, Denver;   GlaxoSmithKline
Active, not recruiting - verified February 2017


Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Completed - verified January 2017


Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster vaccine GSK 1437173A;   Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Sponsor:   GlaxoSmithKline
Completed - verified January 2017


Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster vaccine (GSK1437173A)
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy


Condition:   Herpes Zoster
Interventions:   Biological: GSK 1437173A;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified July 2016


Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers


Condition:   Herpes Zoster
Interventions:   Biological: Herpes zoster vaccine (GSK 1437173A);   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older


Condition:   Herpes Zoster
Intervention:   Biological: Herpes zoster vaccine GSK1437173A
Sponsor:   GlaxoSmithKline
Completed - verified February 2017


Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified April 2017


ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)


Conditions:   Herpes Zoster;   Shingles
Intervention:   Biological: ZOSTAVAX™
Sponsors:   Merck Sharp & Dohme Corp.;   Kaiser Permanente
Active, not recruiting - verified April 2017


Herpes Zoster Vaccine for Bone Marrow Transplant Donors


Condition:   Herpes Zoster
Intervention:   Biological: Zostavax
Sponsor:   University of Sydney
Recruiting - verified May 2017


Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects


Condition:   Herpes Zoster
Intervention:   Procedure: Blood sample
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents


Conditions:   Immunosenescence;   Shingles
Intervention:   Biological: Varicella Zoster Virus Vaccine (Zostavax)
Sponsors:   University of Colorado, Denver;   National Institute on Aging (NIA);   Merck Sharp & Dohme Corp.
Active, not recruiting - verified January 2017


Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster Vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster Vaccine GSK 1437173A
Sponsor:   GlaxoSmithKline
Completed - verified May 2017


Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years


Condition:   Herpes Zoster
Interventions:   Biological: Herpes zoster vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)


Condition:   Shingles
Interventions:   Biological: zoster vaccine live (Oka/Merck);   Biological: Comparator: placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017

Refine Your Search Advanced Search